Abstract: Formylated xanthocillin analogs can be used in the treatment of neurodegenerative diseases. The analogs can be prepared synthetically, and at least some of the analogs can be obtained from a microorganism strain of the Penicillium chrysogenum species.

Abstract: The present invention relates to the Rhodosporidium toruloides CECT 13085 strain, as well as to uses thereof for obtaining microbial biomass rich in triglycerides and for producing oils of a microbial origin in the presence of lignocellulosic biomass hydrolysates.

Abstract: Formylated xanthocillin analogs can be used in the treatment of neurodegenerative diseases. The analogs can be prepared synthetically, and at least some of the analogs can be obtained from a microorganism strain of the Penicillium chrysogenum species.

Abstract: The use of statins as antiepileptic, anticonvulsant, neuroprotector and antioxidant compounds, potentially useful for the prevention and/or treatment of epilepsy, epileptic seizures, convulsions, neurodegenerative diseases, or diseases associated with undesired oxidation, is described.

Abstract: The present invention describes a compound of formula (I) its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for its use in the prevention of: neurodegenerative diseases, cognitive deterioration, diseases associated with undesired oxidation, age-associated pathological processes and progeria, epilepsy, epileptic seizures and convulsions, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, or fungal or viral infections.

Abstract: The present invention relates to a process for obtaining a mixture of fatty acid esters, suitable as a combustible or fuel in diesel cycle engines, comprising: a) the obtaining of a microbial biomass with a triglyceride content equal to or greater than 20% by dry weight, by means of the use of an oleaginous microorganism using glycerin as a carbon source; and b) the conversion of the triglycerides contained in the biomass obtained in step a) into a mixture of fatty acid esters. The invention likewise relates to said oleaginous microorganism, to a process for its selection and to polynucleotides obtained therefrom.

Abstract: The present invention describes a compound of formula (I) its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for use in the prevention of: neurodegenerative diseases, cognitive impairment, diseases associated with undesired oxidation, age-associated pathological processes and progeria, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipidemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, inflammation or inflammatory processes, or epilepsy, epileptic seizures and convulsions.

Abstract: The present invention describes a compound of formula (I) its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for its use in the prevention of: neurodegenerative diseases, cognitive deterioration, diseases associated with undesired oxidation, age-associated pathological processes and progeria, epilepsy, epileptic seizures and convulsions, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, or fungal or viral infections.

Abstract: The invention describes the use of (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl-1-naphthalenyl propanoate derivatives, optionally mono- or di-methylated at the carbon in the alpha position of propanoic acid, of formula (I), where R is CH3CH2CO—, (CH3)2CHCO— or (CH3)3CCO—, its hydroxy acid forms and the pharmaceutically acceptable salts of said hydroxy acids, as neuroprotective compounds potentially useful for the prevention and/or treatment of neurodegenerative diseases, or of diseases associated with an unwanted oxidation or of age-associated pathological processes, or of epilepsy, epileptic seizures or convulsions.

Abstract: The invention relates to a process for obtaining monacolin J derivatives (I), wherein R1 is COR2, wherein R2 is selected from C1-C15 alkyl, C3-C15 cycloalkyl, C2-C15 alkenyl, C2-C15 alkynyl, aryl and heterocyclyl; which comprises producing monacolin J by fermentation from a monacolin J-producing microorganism; and acylating the hydroxyl group present in the C8 position of the monacolin J previously obtained by means of adding a suitable acylating agent to the fermentation medium to obtain the desired monacolin J derivative (I).

Abstract: The use of statins as antiepileptic, anticonvulsant, neuroprotector and antioxidant compounds, potentially useful for the prevention and/or treatment of epilepsy, epileptic seizures, convulsions, neurodegenerative diseases, or diseases associated with undesired oxidation, is described.

Abstract: The present invention relates to a process for obtaining a mixture of fatty acid esters, suitable as a combustible or fuel in diesel cycle engines, comprising: a) the obtaining of a microbial biomass with a triglyceride content equal to or greater than 20% by dry weight, by means of the use of an oleaginous microorganism using glycerin as a carbon source; and b) the conversion of the triglycerides contained in the biomass obtained in step a) into a mixture of fatty acid esters. The invention likewise relates to said oleaginous microorganism, to a process for its selection and to polynucleotides obtained therefrom.

Abstract: An isolated DNA sequence that encodes a peptide with CPC-acetylhydrolase enzymatic activity is disclosed. Also, a method of expressing CPC-acetylhydrolase activity that includes the steps of (a) providing a microorganism that is susceptible to transformation with the isolated DNA sequence and that, upon transformation, expresses the CPC-acetylhydrolase activity encoded by the sequence, and (b) transforming the microorganism with the DNA sequence to cause expression of the CPC-acetylhydrolase activity in the microorganism is disclosed. Also, a method for producing a microorganism with increased capacity to aid in the production of cephalosporin, which method includes the steps of (a) providing a microorganism that has CPC-AH activity by virtue of expression of the DNA sequence or of a fragment thereof coding for the CPC-acetylhydrolase enzyme activity; and (b) inactivating the activity by disrupting expression of the DNA sequence is disclosed.